Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Marky1on Aug 28, 2020 9:56pm

335 Views

Post# 31474385

RE:RE:RE:Zacks

To go from .385$ to 3.00$ that's 675% increase ......kinda hard to believe, but, hey, we have a miracle drug at our feet, and it's going to change the entire drug industry....Soon, and I do believe, in 4 years when I graduate, I think that Otenaproxesul will be in everyones medical cabinet in every bathroom in North America, Japan and Europe, taking over the spot where Aspirin/ Tylenol used to be...Those medicines filling the garbage dumps of the world!
worth many many Billions$.....
bye and have a nice weekend y'all
JM

Bullboard Posts

Changing Europe’s dependency on HREE from China